HLN— AI Stock Forecast & Price Targets
Published 8/14/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live HLN price forecast →
Haleon (HLN) demonstrates resilient fundamentals with strong margins and dividend yield, but near-term headwinds from regulatory concerns and modest growth rates temper upside potential. The technical chart shows consolidation within forecast bands, suggesting limited momentum without clear catalysts.
Hold near $9.70; invalidation below $9.65 would trigger trimming to avoid further downside. Key levels: support at $9.65 (current 20-day SMA), resistance at $9.80 (50-day SMA).
Target 10-11% return over 6 months; catalysts include Q3 earnings beat and regulatory clarity on voluntary recall. If growth accelerates beyond current modest rates, consider accumulation.
Terminal thesis: stable dividend payer with resilient margins in consumer health. Structural risk is slowing top-line growth due to competitive pressures and aging demographics in core categories.
Revenue grew 15.2% QoQ (July 2026), driven by North America and emerging markets, but persistent respiratory weakness offsets gains. Gross margins remain robust at 65.46%, operating margins at 23.31%, supported by pricing power. Balance sheet shows manageable leverage (Debt/Equity=0.50) with strong cash flow generation ($1.8B FCF), though high debt-to-equity ratio (50.195) and negative working capital (-$383M) indicate operational strain. Dividend yield of 2.02% provides income stability, but modest EPS growth (forward EPS=0.623) limits upside potential.
The chart shows a downtrend from the 52-week high ($11.28) to current price ($9.70), with recent consolidation near $9.70. Support at $9.65 and resistance at $9.80 are key levels; forecast bands (yellow) show tight convergence around actual prices, indicating low momentum. The 20-day SMA (-2.28%) is below the price, suggesting short-term weakness, while the 50-day SMA (+1.15%) provides a potential upward bias. RSI at 45.17 indicates neutral sentiment with no extreme overbought/oversold conditions.
Recent earnings show sequential organic growth of 3.1% in Q2, driven by North America and emerging markets, but European demand concerns and respiratory weakness overshadow gains. The consensus rating is 'Moderate Buy' (2 sell, 3 hold, 5 buy), indicating cautious optimism. However, the stock's recent price action reflects market skepticism about sustainable growth, with a -4.06% YTD performance.
- North America organic sales growth accelerated to 3.1% QoQ (July 2026) driven by improved execution, per earnings call
- Regulatory scrutiny from voluntary recall impacting brand perception
- Slowing top-line revenue growth limiting upside potential
- Sensitivity to broader discretionary consumer spending cycles
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord